The combination treatment-induced systemic immune response was evaluated by measuring the secretion of serum proinflammatory cytokines with ELISA assay, including tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and interleukin-6 (IL-6), that play vital roles in anti-cancer immunity. This evidence concerns the gene IL6 and cancer.